晶珠肝泰舒胶囊治疗肝炎肝硬变60例

观察了服用晶珠肝泰舒胶囊治疗慢性肝炎 ５２例、肝炎后肝硬化（代偿期） ８例。经 ３个月（ １疗程）治疗,全部病例临床症状、体征与肝功改善均较显著,显效率达８３ ３３％。其中对肝炎后肝硬变作用明显,提示晶珠肝泰舒胶囊在保肝同时,还有一定抗肝纤维化作用。对乙肝病毒血清标志物ＨＢＶ－ＤＮＡ阴转率１２ ５％,ＨＢｓＡｇ阴转率１５．７８％,ＨＢｃＡｇ转阴率７ ４％,提示晶珠肝泰舒胶囊具有抗病毒作用。     

朱丹溪善用风药治疗血证谈

复习朱丹溪有关医学文献 ,阐发其应用风药治疗血证的机制 ,主要有 :风药直接止血 ;风药升阴散火止血 ;风药散火解毒、凉血止血 ;风药炒黑止血 ;风药振脾益气止血 ;祛除致病因素 ;其它。     

金石散胶囊溶解胆石的临床研究

自１９８７年迄今,用金石散（４－６胶囊／次,２－３次／天）治疗胆结石患者１７７例,３月为一疗程,共２－４疗程。治疗前后均经Ｂ超检查以判断疗效。结果显示：１．服药一月,９０％病人的发热、腹胀、疼痛等临床症状消失。２、６２例胆囊结石经服药平均８．１８＋７．１４月后,３例结石完全消失（４．８４％）,３７例结石减少变小,总有效率６４．５２％;而临床类型型相似的另外２３例,用ＵＤＣＡ治疗作为对照组,总有效率     

胃肠宁胶囊治疗肝胃郁热型胃脘痛的临床观察附:170例病例报告

对照观察了中药胃肠宁胶囊和三九胃泰治疗肝胃郁热型胃脘痛患者１７０例的临床疗效,结果治疗组（胃肠宁胶囊组）１０４例,显效率为７５．９６％,对照组（三九胃泰组）６６例,显效率为３６．３６％,二者比较有高度统计学意义（Ｐ〈０．０１）,表明胃肠宁胶囊治疗肝胃郁热型胃脘痛的疗效优于三九胃泰。通过治疗前后肝胃郁热主症及其引起的其它症状的比较及慢性浅表性胃炎病理诊断比较,结果表明,具有疏肝解郁,清热和胃降逆之功     

薄层扫描法测定清开灵注射液中栀子甙的含量

目的：测定清开灵注射液中栀子甙的含量。方法：采用双波长薄层扫描法,测定波长为２４０ ｎｍ ,参比波长为３１０ ｎｍ ,狭缝为１－２ ｍ ｍ ×１－２ ｍ ｍ ,ＳＸ＝ ３ 。结果：在１ ～５ μｇ 范围内呈良好的线性关系,平均回收率为９９ ．８９ ％ 。ＲＳＤ＝ １－１９ ％ （ｎ ＝５） 。结论：本法简便、快速、灵敏、结果准确可靠。     

Randomized clinical trial of the 350-mm2 versus the 500-mm2 Baerveldt implant: longer term results: Is bigger better?

OBJECTIVE: To report the longer term results of a randomized, clinical trial comparing the 350-mm2 and the 500-mm2 Baerveldt glaucoma implants. DESIGN: Extended follow-up on a randomized, controlled trial. PARTICIPANTS: Between March 1991 and April 1993, 107 patients with uncontrolled intraocular pressure (IOP) due to non-neovascular glaucoma associated with aphakia, pseudophakia, or failed filters were randomly assigned for surgical placement of either the 350-mm or the 500-mm2 Baerveldt implant at the Doheny Eye Institute. METHODS: A random-numbers table was used to assign each patient to one of the two groups. Preoperative IOPs and visual acuities were recorded. Clinical records were reviewed to ascertain postoperative IOPs, visual acuities, number of medications used, and implant-related complications that occurred throughout the follow-up period. MAIN OUTCOME MEASURES: Success was defined as IOP of 6 mmHg or greater and of 21 mmHg or less in two or more consecutive follow-up visits without further glaucoma surgery or loss of light perception attributable to glaucoma. RESULTS: The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05). Average follow-up was 37 months (range, 1-76 months) for the 350-mm2 group and 34 months (range, 5-77 months) for the 500-mm2 group. The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years. Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group. Complications during the 5-year follow-up were also statistically similar. CONCLUSIONS: The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control. Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation. Visual acuities, implant-related complications, and average IOPs were statistically indistinguishable between the two groups.     

Episcleritis in childhood

OBJECTIVE: To describe the characteristics and systemic disease associations of episcleritis in childhood. DESIGN: Retrospective, observational case series. PARTICIPANTS: Twelve children diagnosed with episcleritis between July 1981 and June 1998. METHODS/TESTING: Complete eye and systemic evaluations. MAIN OUTCOME MEASURES: Characteristics of episcleritis and presence and nature of concurrent systemic disease. RESULTS: The 12 children (10 boys and 2 girls) ranged in age from 13 months to 16 years. Five children had bilateral simple episcleritis, one had bilateral nodular episcleritis, and six had unilateral simple episcleritis. The eye examination was otherwise normal and recovery was uneventful in all cases. Six of the nine children older than 5 years of age had one of the following rheumatologic diseases: systemic lupus erythematosus, juvenile rheumatoid arthritis, spondyloarthropathy, inflammatory bowel disease, rheumatic fever, or polyarteritis nodosa. All three children younger than 5 years of age had simple episcleritis, an antecedent viral illness, and presented within 2 months of each other. CONCLUSIONS: Episcleritis is a rare occurrence in childhood, especially in children younger than 5 years of age. In older children, it is frequently associated with rheumatologic disease.     

Comparative surface thrombogenicity of implanted vascular grafts.

In order to study the comparative thrombogenicity of neointimal surfaces that develop with three types of vascular graft materials (ultralightweight knitted dacron, knitted dacron external velour, and expanded Teflon), 36 female mongrel dogs had their infrarenal aortas alternately replaced with one of the three grafts. At the end of 3 or 6 months, the grafts were removed and the surface thrombogenicity of the neointimal surface was determined. Each graft was examined visually and microscopically for evidence of “healing.” At 6 months the external velour graft is lined more frequently than the other two grafts. The external velour graft has a markedly better incidence of cellular healing noted microscopically than the other two grafts at both time intervals. While the expanded Teflon has an initially lower surface thrombogenicity (probably due to the characteristics of Teflon surface), at 6 months, the velour graft has the lowest surface thrombogenicity. This is most likely due to cellular healing. Of all the completely lined grafts at both time intervals, the surface thrombogenicity of the velour grafts was most like that of the normal aorta. The velour graft appears to develop the least thrombogenic neointimal surface while becoming most frequently healed with a cellular neointimal surface.     

清开灵注射液治疗急性脑卒中疗效观察

目的 评价清开灵注射液治疗急性脑卒中的疗效。方法 把急性脑卒中患者88例随机分成清开灵治疗组58例(脑出血20例，脑梗塞38例)、对照组30例(脑出血12例，脑梗塞18例)。在对照组治疗的基础上加用清开灵注射液40ml静脉滴注，每天1～2次，连用14d。分别在治疗前、治疗后14d进行神经功能缺损评分，观察其临床效果。结果 治疗组的显效率、基本痊愈十显效率、总有效率均显著高于对照组。结论 清开灵注射液能提高急性脑卒中的治愈率，降低致残率、死亡率，安全有效，值得推广应用。